We would love to hear your thoughts about our site and services, please take our survey here.
IMO, it won’t be a case of either MRNA, or DNA as an available treatment option and there will be room for both as ammo against melanoma. In the same way that there are often multiple treatment options for other diseases. Assuming of course that trial data proves they both work well.
The publicity is positive on a number of fronts. Scancell now need to get their own data published. We already know that should be this year and we’re already in April, so it’s just a handful of months away.
Schlum - doubt it.
From the AGM Statement made in January:
“Trading is in-line with expectations. Further information on trading will be provided when interim results for the six months ending 31 March 2024 are announced”
Interims will be in June.
Better to be presenting / speaking to an audience who have chosen to be in the room for that topic, than smiling at folks wandering post your poster, looking for refreshments. Big difference imo. It’s a talk, 30mins allocated for it and another big chance to impress / raise the Company profile. Don’t care what the market thinks of the RNS today!
Jatw - lots of different words in your response but seeing straight through that, you are saying the exact same thing I posted previously ie. you have no confidence in the growth and status of the Company in the short, medium or even long term. In response you have simply underlined that.
But you remain a Shareholder!
PS: My user name has nothing to do with football.
Jatw you say “ they are operating a small company in some small market niches and I dont see anything here to change that even if they do increase sales by low teen % for a few years”
Translates to you having no confidence in the growth and status of the Company in the short, medium or even long term.
Are you actually a Shareholder here?
Greater clarity……
https://www.londonstockexchange.com/news-article/DSM/result-of-meeting-special-dividend-announcement/16406474
Wasn’t the Downing wind down blocked by Milkwood?
https://www.morningstar.co.uk/uk/news/AN_1712161896305451400/downing-strategic-wind-down-blocked-by-new-shareholder-milkwood.aspx
Can’t deny there is risk attached to M&A. However, there can also be reward that propels a company forward, rather than treading water (and the SP doing the same or worse). From what we’ve seen since Dec 22, they seem to have got it right with HL Healthcare.
Wouldn’t class Earol as a small brand Jatw, hence why they bought it and as I previously said, there was hint of further M&A activity from Jerry Randall. That would be in addition to any in-house product development / launch which they say is “ready”.